Rybelsus Lawsuit 2026 | Gastrointestinal Injuries and Vision Loss Claims

Rybelsus Lawsuit Overview

Rybelsus is an oral GLP-1 receptor agonist containing semaglutide, the same active ingredient used in Ozempic, and is manufactured by Novo Nordisk.

Lawsuits involving Rybelsus fall within a broader wave of litigation against drug companies that market GLP-1 medications, with allegations centered on serious gastrointestinal and neurological injuries.

Plaintiffs allege that these drugs can cause gastroparesis (stomach paralysis), delayed gastric emptying, and other severe complications that extend well beyond temporary or expected side effects.

Many lawsuits assert that while GLP-1 drugs were designed to slow digestion, the severity, duration, and clinical consequences of these effects were not adequately disclosed to patients or prescribing physicians.

Some filings also raise concerns about vision loss, including optic nerve injuries, which are being addressed in separate but related federal proceedings.

The core legal theory across these cases is a failure-to-warn claim, grounded in what manufacturers knew or should have known based on available data.

According to the allegations, information from clinical trials, post-marketing surveillance, and regulatory communications should have prompted stronger warnings about serious gastrointestinal risks.

Regulatory scrutiny has expanded internationally, with agencies such as the European Medicines Agency examining safety signals associated with GLP-1 medications.

More than 3,000 active lawsuits have been filed against Novo Nordisk related to Ozempic and other GLP-1 drugs, reflecting the growing scope of this litigation trend.

Rybelsus claims are being coordinated with related cases through federal multidistrict litigation (MDL), which centralizes shared factual and scientific issues while preserving individual injury claims.

Allegations commonly raised in Rybelsus and related GLP-1 lawsuits include:

• Failure to adequately warn about the risk of severe gastrointestinal side effects, including gastroparesis and ileus
• Allegations that drug manufacturers knew or should have known about these risks based on clinical trials and post-approval data
• Claims that delayed gastric emptying led to persistent vomiting, abdominal pain, malnutrition, and long-term digestive impairment
• Reports of vision loss and optic nerve injuries associated with GLP-1 use, addressed in separate federal proceedings
• Centralization of cases in multidistrict litigation (MDL) to evaluate shared evidence while assessing each claim individually

Together, these allegations place Rybelsus within a larger legal examination of GLP-1 drug safety and the adequacy of risk disclosures made to patients and healthcare providers.

Other Drugs and Manufacturers Named in the GLP-1 Lawsuits

GLP-1 drugs have seen rapid growth in use as both a weight loss drug option and a diabetes treatment, with many patients using them for weight loss and long-term metabolic goals under medical supervision.

Other GLP-1 drugs named in related litigation commonly include:

• Ozempic (Novo Nordisk)
• Wegovy (Novo Nordisk)
• Trulicity (Eli Lilly)
• Mounjaro (Eli Lilly)
• Zepbound (Eli Lilly)
• Saxenda (Novo Nordisk)
• Victoza (Novo Nordisk) (often discussed among GLP-1 products and manufacturer portfolios)

Alleged Injuries and Medical Conditions Linked to GLP-1 Drugs

As GLP-1 medications have become more widely prescribed (both as weight loss medications and as a prescription drug option for diabetes), medical researchers and clinicians have published and discussed complications that can extend beyond temporary nausea.

The current wave of lawsuits filed (including federal lawsuits) builds on that growing body of discussion, along with adverse event reports, and frames these issues as alleged severe outcomes that warrant closer scrutiny.

In the Rybelsus lawsuit and other lawsuits involving Ozempic and related semaglutide drugs, plaintiffs typically point to medical evidence such as symptom timelines, ER visits, and specialist diagnoses, rather than relying on general complaints.

The litigation tends to focus on documented gastrointestinal adverse reactions and other severe injuries supported by objective medical testing, while defendants dispute causation and emphasize case-specific factors.

Severe Digestive Conditions Alleged in GLP-1 Lawsuits

Many gastroparesis lawsuits and related filings involve claims of serious gastrointestinal motility disorders, not mild appetite suppression or brief nausea during dose escalation.

Plaintiffs allege gastroparesis (also known as stomach paralysis), a condition where the stomach does not move food normally, leading to delayed emptying and symptoms that can become disabling.

Another core injury is ileus, where the intestines slow or stop and symptoms can resemble an intestinal blockage, sometimes requiring urgent evaluation.

Complaints also commonly reference obstruction or pseudo-obstruction patterns, where patients report worsening abdominal pain, distension, and inability to pass stool or gas, along with repeat medical visits and escalating treatment needs.

In many cases, the proof centers on objective medical testing (for example, a gastric emptying study) and records documenting ER care and medical intervention.

Gastrointestinal complications commonly alleged include:

• Severe vomiting that does not resolve with routine care
• Inability to tolerate food or liquids, sometimes requiring IV fluids
• Progressive abdominal pain and abdominal distension
• Dehydration and electrolyte abnormalities needing treatment
• Repeated emergency room visits and ongoing medical treatment
• Hospital admission for monitoring, imaging, and symptom control
• Surgical consultation or surgical evaluation for suspected obstruction/pseudo-obstruction
• Significant medical expenses tied to diagnostics, admissions, and follow-up care

Vision Loss Potentially Linked to GLP-1 Usage

Some reported cases and subsequent claims allege an association between GLP-1 use and non-arteritic anterior ischemic optic neuropathy (NAION), which is why you may see references to Ozempic vision loss lawsuits alongside GI allegations.

NAION is an eye condition involving reduced blood supply to the optic nerve; it often presents as sudden, painless vision loss or a shadow/curtain effect in one eye, sometimes noticed upon waking.

Because the injury reflects ischemic damage to optic nerve tissue, vision changes may be sudden and, in some cases, progress to permanent vision loss despite treatment, making it a very different category of allegation than gastrointestinal symptoms.

Procedurally, these vision-loss cases are being handled separately from the GI claims.

The U.S. Judicial Panel on Multidistrict Litigation created a distinct MDL for NAION allegations involving GLP-1 medications in the Eastern District of Pennsylvania.

That means the NAION cases proceed on their own track in federal court, while the GI cases remain centralized in the separate GLP-1 gastrointestinal MDL.

Do You Qualify for a Rybelsus Lawsuit?

If you took Rybelsus and later began to develop severe digestive problems or vision changes, you may be eligible to file a claim within the broader GLP-1 legal process.

Rybelsus is an oral semaglutide product from manufacturer Novo Nordisk, and complaints involving Ozempic, Wegovy, and Rybelsus generally focus on alleged outcomes more serious than short-term nausea.

Many lawsuits allege that some patients experienced severe gastrointestinal injuries such as persistent vomiting, repeated emergency room visits, and worsening stomach pain that required escalated care.

Other claims center on motility disorders, including suspected or diagnosed intestinal obstruction, ileus-like symptoms, or patterns described as cyclic vomiting syndrome, depending on what clinicians documented.

Some people seek review after sudden vision changes tied to reduced blood flow to the optic nerve, including NAION-type allegations.

Qualification may depend on documented diagnoses, treatment history, and objective testing reflected in your medical records.

It also matters when symptoms started compared to when you used the drug and whether your providers documented a consistent progression.

Even if you were one of many Ozempic users who later switched therapies (or used Ozempic, Wegovy or other drugs before or after Rybelsus), each case is evaluated individually under the same umbrella framework, including proceedings coordinated by the panel on multidistrict litigation.

Evidence Commonly Reviewed in GLP-1 Lawsuits

Evidence is critical in GLP-1 cases because attorneys must connect the alleged injury to a clear timeline and clinical proof, not just symptom reports.

Most reviews start with medication exposure (exact start/stop dates and dosing), then compare that timeline to symptom onset and escalation.

Diagnosis matters, and lawyers look for diagnostic confirmation (imaging, endoscopy findings, gastric motility testing, and ophthalmology workups) that supports what is being claimed.

Consistent documentation also helps counsel evaluate issues like causation, alternative explanations, and whether the product labeling adequately warned about the risks alleged.

Common evidence includes:

• Pharmacy and prescribing history for Rybelsus and other GLP-1 medications, including Ozempic Wegovy and Rybelsus
• Documentation of symptom onset, including escalation to persistent vomiting, severe stomach pain, or dehydration
• ER and hospital records, including repeat emergency room visits, admissions, and discharge summaries
• Imaging reports (CT, X-ray, ultrasound) evaluating obstruction, ileus, or intestinal obstruction patterns
• GI specialist notes, endoscopy reports, and motility testing results
• Gastric emptying studies and related objective testing showing delayed emptying or motility impairment
• Ophthalmology and neuro-ophthalmology records, including visual field testing and notes referencing optic nerve findings
• Records of ongoing treatment, follow-up care, and documented health complications over time

Damages in Rybelsus Lawsuit Claims

In pharmaceutical injury cases, “damages” refers to the losses a person claims resulted from the alleged injury.

Attorneys evaluate damages by reviewing medical records, bills, prognosis, and how the condition affected daily function, work capacity, and long-term care needs.

The value of any claim depends on the specific facts: the severity of symptoms, whether hospitalization or procedures occurred, and whether treatment is still ongoing.

In severe GI cases, damages may turn on the scope of care required for gastrointestinal risks that allegedly progressed into serious motility disorders; in vision cases, it may hinge on functional impairment tied to optic nerve injury and related limitations.

Lawyers also consider whether a patient used other “popular weight loss drugs” in the same class and how that impacts the timeline and proof in the case.

Potential damages may include:

• Past and future medical costs related to GI or vision care
• Future treatment and monitoring expenses (specialists, testing, procedures)
• Lost income from missed work and time away from normal activities
• Reduced earning capacity if limitations persist
• Diminished quality of life due to ongoing symptoms, diet restrictions, or vision impairment

TorHoerman Law: Investigating the Rybelsus Lawsuit

TorHoerman Law is investigating claims involving alleged GLP-1-related gastrointestinal injuries and vision loss, including cases involving Rybelsus and other semaglutide products such as Ozempic Wegovy.

Our review starts with your medication history, symptom timeline, and the clinical testing that supports (or rules out) a motility disorder or optic nerve event.

We look closely at what your treating providers documented (diagnoses, objective findings, and the treatment required after symptoms escalated), because these cases rise and fall on medical proof.

If you believe you experienced severe GI complications or vision changes after using Rybelsus, our team can walk you through the next steps and provide a free consultation based on the medical evidence you have.

Contact our team today, or use the chatbot on this page.